Table 1:
Baseline characteristics
| Erie (n=37) | Butler (n=50) | |
|---|---|---|
| Sex-Male n (%) | 37 (100%) | 48(96%) |
| Age-Mean (SD) | 68.9 (6.4) | 65.9 (10.3) |
| Race-White n (%) | 35 (94.6%) | 44 (88.0%) |
| Comorbidities n (%) | ||
| Hypertension | 37 (100%) | 47 (94.0%) |
| Hyperlipidemia | 37 (100%) | 47 (94.0%) |
| Mental health diagnosis | 12 (32.4%) | 21 (42.0%) |
| Nephropathy | 22 (59.5%) | 17 (34.0%) |
| Coronary artery disease | 15 (40.5%) | 17 (34.0%) |
| Stroke | 7 (18.9%) | 6 (12.0%) |
| Peripheral arterial disease | 7 (18.9%) | 10 (20.0%) |
| A1C % Mean (SD) | 10.4 (1.8) | 9.8 (0.97) |
| A1C mmol/mol Mean (SD) | 90 (19.7) | 84 (10.6) |
| LDL mg/dL Mean (SD) | 86.9 (35.9) | 90.1 (37.2) |
| Weight lbs Mean (SD) | 228.5 (43.8) | 229.8 (51.4) |
| Systolic blood pressure mmHg | 134.3 (13.9) | 127.7 (17.1) |
| Mean (SD) | ||
| Medications n (%) | ||
| Insulin | 25 (67.6%) | 37 (74%) |
| Metformin | 24 (64.9%) | 29 (58.0%) |
| Sulfonylurea | 16 (43.2%) | 16 (32.0%) |
| GLP-1 receptor agonist | 1 (2.7%) | 1 (2.0%) |
| SGLT2 inhibitor | 1 (2.7%) | 0 (0%) |